Oxidative stress status in metastatic breast cancer patients receiving palliative chemotherapy and its impact on survival rates.
Antineoplastic agents are known to induce the production of free radicals leading to cell damage. These adverse effects may fuel the acquisition of new mutations and the development of treatment resistances. We selected 30 metastatic breast cancer patients receiving palliative chemotherapy, and paired blood samples, before and after chemotherapy, were extracted. We analysed DNA, lipid and protein oxidative damage markers and determined the extent of antioxidant and repair defences activation at the systemic level. We found that the DNA repair activity of the KU86 enzyme was significantly lower after chemotherapy and the antioxidant capacity of the plasma was significantly higher after treatment. Cox regression analysis revealed a significant effect of KU86 activity on the survival rates of those patients who received anthracyclines as part of their treatment. The high clinical heterogeneity of metastatic breast cancer patients warrants further studies to clarify the role of DNA repair and systemic antioxidant capacities during chemotherapy.
Department of Oncology, Complejo Hospitalario de Jaen, Jaen, Spain. lvera@correo.ugr.es
Laura
L
Vera-Ramirez
Pedro
P
Sanchez-Rovira
M Carmen
MC
Ramirez-Tortosa
Cesar L
CL
Ramirez-Tortosa
Sergio
S
Granados-Principal
Jose A
JA
Lorente
Jose L
JL
Quiles
D000328:Adult; D000368:Aged; D034961:Antigens, Nuclear / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000975:Antioxidants / Q000378:metabolism; D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D004260:DNA Repair; D004273:DNA, Neoplasm / Q000097:blood / Q000235:genetics; D004268:DNA-Binding Proteins / Q000378:metabolism; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D000072200:Ku Autoantigen; D008875:Middle Aged; D009362:Neoplasm Metastasis; D018384:Oxidative Stress / Q000187:drug effects* / Q000502:physiology; D010166:Palliative Care; D015996:Survival Rate
D034961:Antigens, Nuclear; D000975:Antioxidants; D004273:DNA, Neoplasm; D004268:DNA-Binding Proteins; C000606509:Xrcc6 protein, human; D000072200:Ku Autoantigen